Roman Yatsyshyn

A phase III randomized study to evaluate the efficacy and safety of CT-P13 compared with reference infliximab in patients with active rheumatoid arthritis: 54-week results from the PLANETRA study

Dae‐Hyun Yoo, Artur Racewicz, Jan Brzezicki et al. · Arthritis Research & Therapy · 2016 · 171 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

A randomised, double-blind, phase III study comparing SB2, an infliximab biosimilar, to the infliximab reference product Remicade in patients with moderate to severe rheumatoid arthritis despite methotrexate therapy

Jung‐Yoon Choe, Nenad Prodanović, Jaroslaw Niebrzydowski et al. · Annals of the Rheumatic Diseases · 2015 · 166 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Safety, immunogenicity and efficacy after switching from reference infliximab to biosimilar SB2 compared with continuing reference infliximab and SB2 in patients with rheumatoid arthritis: results of a randomised, double-blind, phase III transition study

Josef S Smolen, Jung‐Yoon Choe, Nenad Prodanović et al. · Annals of the Rheumatic Diseases · 2017 · 122 citations · Full text

Life Sciences, Clinical Sciences, Immunology +7

Efficacy, pharmacokinetics and safety of subcutaneous versus intravenous CT-P13 in rheumatoid arthritis: a randomized phase I/III trial

René Westhovens, Piotr Wiland, Marek Zawadzki et al. · Lara D. Veeken · 2020 · 56 citations · Full text

Medicine, Pharmacokinetics, Pharmacotherapy +14

Comparing biosimilar SB2 with reference infliximab after 54 weeks of a double-blind trial: clinical, structural and safety results

Josef S Smolen, Jung‐Yoon Choe, Nenad Prodanović et al. · Lara D. Veeken · 2017 · 54 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +12